Emerging principles for the design of promiscuous HLA-DR-restricted peptides: An example from the major bee venom allergen

European Journal of Immunology

Volumn 32, Issue 12, 2002, Pages 3699-3707

  Texier, Catherine ^a   Povelle Moratille, Sandra ^a   Buhot, Cécile ^a   Castelli, Florence A ^a   Pecquet, Catherine ^b   Ménez, André ^a   Leynadier, Francisque ^b   Maillère, Bernard ^a  

^a CEA SACLAY   (France)

^b HÔPITAL TENON   (France)

Author keywords

Allergy; Bee venom; Epitope; HLA DR; Peptide

Indexed keywords

ALLERGEN; BEE VENOM; CD4 ANTIGEN; EPITOPE; HLA DR ANTIGEN; IMMUNOGLOBULIN E; PEPTIDE;

ADULT; ALLERGY; AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE MUTATION; HELPER CELL; HUMAN; IMMUNOTHERAPY; MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 0036914360     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200212)32:12<3699::AID-IMMU3699>3.0.CO;2-V     Document Type: Article

References (41)

1. Arnon, R. and Van Regenmortel, M. H., Structural basis of antigenic specificity and design of new vaccines. FASEB J. 1992. 6: 3265-3274.
2. Sloan-Lancaster, J. and Allen, P. M., Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 1996. 14: 1-27.
3. Gahery-Segard, H., Pialoux, G., Charmeteau, B., Sermet, S., Poncelet, H., Raux, M., Tartar, A., Levy, J. P., Gras-Masse, H. and Guillet, J. G., Multiepitopic B- and T cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 2000. 74: 1694-1703.
4. Ressing, M. E., van Driel, W. J., Brandt, R. M., Kenter, G. G., de Jong, J. H., Bauknecht, T., Fleuren, G. J., Hoogerhout, P., Offringa, R., Sette, A., Celis, E., Grey, H., Trimbos, B. J., Kast, W. M. and Melief, C. J., Detection of T helper responses, but not of human papillomavirus- specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 2000. 23: 255-266.
5. Muller, U., Akdis, C. A., Fricker, M., Akdis, M., Blesken, T., Bettens, F. and Blaser, K., Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 1998. 101: 747-754.
6. Oldfield, W. L., Kay, A. B. and Larche, M., Allergen-derived t cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 2001. 167: 1734-1739.
7. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A., Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989. 19: 2237-2242.
8. Kilgus, J., Jardetzky, T., Gorga, J. C., Trzeciak, A., Gillessen, D. and Sinigaglia, F., Analysis of the permissive association of a malaria T cell epitope with DR molecules. J. Immunol. 1991. 146: 307-315.
9. Lamonaca, V., Missale, G., Urbani, S., Pilli, M., Boni, C., Mori, C., Sette, A., Massari, M., Southwood, S., Bertoni, R., Valli, A., Fiaccadori, F. and Ferrari, C., Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999. 30: 1088-1098.
10. de Lalla, C., Sturniolo, T., Abbruzzese, L., Hammer, J., Sidoli, A., Sinigaglia, F. and Panina-Bordignon, P., Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction. J. Immunol. 1999, 163: 1725-1729.
11. Texier, C., Pouvelle, S., Busson, M., Herve, M., Charron, D., Menez, A. and Maillere, B., HLA-DR restricted peptide candidates for bee,venom immunotherapy. J. Immunol. 2000. 164: 3177-3184.
12. Manici, S., Sturniolo, T., Imro, M. A., Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P. and Protti, M. P., Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 1999. 189: 871-876.
13. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A. and et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994. 11: 751-761.
14. Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F. and Hammer, J., Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999. 17: 555-561.
15. Rammensee, H. G., Friede, T. and Stevanoviic, S., MHC ligands and peptide motifs: first listing. Immunogenetics 1995. 41: 178-228.
16. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L. and Wiley, D. C., Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994. 368: 215-221.
17. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M. and Sette, A., Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998. 160: 3363-3373.
18. Geluk, A., van Meijgaarden, K. E., Southwood, S., Oseroff, C., Drijfhout, J. W., de Vries, R. R., Ottenhoff, T. H. and Sette, A., HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 1994. 152: 5742-5748.
19. Malcherek, G., Gnau, V., Stevanovic, S., Rammensee, H. G., Jung, G. and Malms, A., Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J. Immunol. 1994. 153: 1141-1149.
20. Texier, C., Pouvelle- Moratille, S., Busson, M., Charron, D., Menez, A. and Maillere, B., Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 2001. 31: 1837-1846.
21. Muller, U., Helbling, A. and Berchtold, E., Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 1992. 89: 529-535.
22. Vogt, A. B., Kropshofer, H., Kalbacher, H., Kalbus, M., Rammensee, H. G., Coligan, J. E. and Martin, R., Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 1994. 153: 1665-1673.
23. Kammerer, R., Kettner, A., Chvatchko, Y., Dufour, N., Tiercy, J. M., Corradin, G. and Spertini, F., delineation of PLA2 epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy. Clin. Exp. Allergy 1997. 27: 1016-1026.
24. Carballido, J. M., Carballido-Perrig, N., Kagi, M. K., Meloen, R. H., Wuthrich, B., Heusser, C. H. and Blaser, K., T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J. Immunol. 1993. 150: 3582-3591.
25. Dhillon, M., Roberts, C., Nunn, T. and Kuo, M., Mapping human T cell epitopes on phospholipase A2: the major bee-venom allergen. J. Allergy Clin. Immunol. 1992. 90: 42-51.
26. Marshall, K. W., Liu, A. F., Canales, J., Perahia, B., Jorgensen, B., Gantzos, R. D., Aguilar, B., Devaux, B. and Rothbard, J. B., Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol. 1994. 152: 4946-4957.
27. Kurata, A. and Berzofsky, J. A., Analysis of peptide residues interacting with MHC molecule or T cell receptor. Can a peptide bind in more than one way to the same MHC molecule? J. Immunol. 1990. 144: 4526-4535.
28. d restricted determinants and T cell epitopes from the major bee venom allergen. Int. Immunol. 1999. 11: 1313-1325.
29. Raddrizzani, L., Sturniolo, T., Guenot, J., Bono, E., Gallazzi, F., Nagy, Z. A., Sinigaglia, F. and Hammer, J., Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J. Immunol. 1997. 159: 703-711.
30. McFarland, B. J., Sant, A. J., Lybrand, T. P. and Beeson, C., Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry 1999. 38: 16663-16670.
31. Robertson, J. M., Jensen, P. E. and Evavold, B. D., DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 2000. 164: 4706-4712.
32. Pogue, R. R., Eron, J., Frelinger, J. A. and Matsui, M., Aminoterminal alteration of the HLA-A*0201 -restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA 1995. 92: 8166-8170.
33. Sarobe, P., Pendleton, C. D., Akatsuka, T., Lau, D., Engelhard, V. H., Feinstone, S. M. and Berzofsky, J. A., Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 1998. 102: 1239-1248.
34. Maillere, B., Mourier, G., Herve, M. and Menez, A., Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol. Immunol. 1995. 32: 1377-1385.
35. Ahlers, J. D., Takeshita, T., Pendleton, C. D. and Berzofsky, J. A., Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. USA 1997. 94: 10856-10861.
36. Nicholson, L. B., Waldner, H., Carrizosa, A. M., Sette, A., Collins, M. and Kuchroo, V. K., Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc. Natl. Acad. Sci. USA 1998. 95: 264-269.
37. Slansky, J. E., Rattis, F. M., Boyd, L. F., Fahmy, T., Jaffee, E. M., Schneck, J. P., Margulies, D. H. and Pardoll, D. M., Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000. 13: 529-538.
38. Tangri, S., Ishioka, G. Y., Huang, X., Sidney, J., Southwood, S., Fikes, J. and Sette, A., Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 2001. 194: 833-846.
39. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K., An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995. 3: 397-405.
40. Janssen, E. M., van Oosterhout, A. J., van Rensen, A. J., van Eden, W., Nijkamp, F. P. and Wauben, M. H., Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J. Immunol. 2000. 164: 580-588.
41. Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P. and Steinman, L., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 2000. 6: 1176-1182.